Kiyohara, M H
Dillard, C
Tsui, J
Kim, S R
Lu, J
Sachdev, D
Goodglick, L
Tong, M
Torous, V F
Aryasomayajula, C
Wang, W
Najafzadeh, P
Gordon, L K
Braun, J
McDermott, S
Wicha, M S
Wadehra, M
Article History
Received: 6 January 2016
Revised: 21 March 2017
Accepted: 25 March 2017
First Online: 12 June 2017
Competing interests
: MW, LKG and JB are inventors on the University of California patents related to the anti-EMP2 IgG1 antibody presented in this work. They are also founders of Paganini Biopharma. MSW has financial holdings and is a scientific advisor for OncoMed Pharmaceuticals, Verastem, Paganini and MedImmune and receives research support from Dompe Pharmaceuticals and MedImmune. The remaining authors declare no conflict of interest.